- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05697952
E1K Intra Articular(IA) Treatment for Knee Osteoarthritis
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of E1K After Single Dose in Patients With Knee Osteoarthritis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female adult, who is 40 years~70 years of age(inclusive of both age) at the date of consent
Subject who diagnosed knee osteoarthritis according to ACR criteria at screening visit, having pain in the knee and osteophyte formation in the X-ray, and one or more criteria as follows :
- Aged >50
- Morning stiffness < 30 minutes
- Crepitus on knee motion
- Prior to administration of IP, Subject with 50mm~70mm of 100mm Pain Visual Analog Scale (VAS) during activity of the knee of osteoarthritis(target lesion).
- Subject with Grade 2 or Grade 3 on the knee osteoarthritis(target lesion) by Kellgren & Lawrence radiographic grading system
- Subject who has pain on the knee osteoarthritis at least for 6 months before screening visit.
- Subject who agrees not to use rescue medication within 48-hour of regular visit date.
- Subject who agrees not to have ancillary physiotherapy
One-sided knee osteoarthritis subject or both-sided knee osteoarthritis subject who can designate the Target Lesion to one side, according to the follow criteria.
- Designate the one with a higher 100 mm Pain Visual Analog Scale (VAS) than another, as the target lesion.
- If 100 mm Pain Visual Analog Scale (VAS) is the same, designate the one with a higher Kellgren & Lawrence Grade than another, as the target lesion.
- If both 100 mm Pain Visual Analog Scale (VAS) and Kellgren & Lawrence Grade are the same, designate the one that causes more clinical symptoms other than pain.
- If above criteria are all the same, designate the right knee as the target lesion.
- Subject who has voluntarily written informed consent for study participation.
Exclusion Criteria:
- Subject who has secondary knee osteoarthritis such as inflammatory or infectious joint disease or rheumatoid arthritis.
- Subject who has surgical history(ex. knee replacement surgery) on the knee osteoarthritis lesion(target lesion).
- Subject who has conditions that can affect the joints(gout, recurrent caustic gout, joint fracture, primary osteochondrosis, Paget's disease, ochronosis, acromegaly, hematochromatosis, Wilson's disease, genetic disease(ex: hyperkinesia) and collagen gene related disorders.
- Subject whose BMI greater than or equal to 30kg/m2 at screening.
Subject who is applicable to the followings prior to first day of IP administration.
- Intra-articular injected hyaluronic acid, cell therapy and gene therapy within 6 months prior to IP administration
- Intra-articular injected steroids into the knee osteoarthritis lesion(target lesion) within 3 months prior to IP administration
- Administered NSAIDs or glucosamine, chondroitin sulfate, oral steroid within 14 days prior to IP administration.
- Administered analgesics within 1 days prior to IP administration
- Subject who has a psychological disorder(alcohol or drug addiction) and is judged by the investigator to have problems with the safety of the subject or to cause confusion in the interpretation of clinical trial results
- Subject who has osteoarthritis on the other sites not knee(ex. Hip joint) or has pain due to other disorder so that the investigator determined not suitable for participation of the clinical trial.
- Subject who has uncontrolled type 1 or type 2 diabete mellitus at screening visit(Glycated Hemoglobin (HbA1c) > 8%)
- Subject has a positive test result for HIV antibody or hepatitis B antigen, hepatitis C antibody.
- Subject who has malignant tumor history within 5 year prior to screening visit.
- Subject who is participated in other clinical trials within 30 days prior to screening.
- As a result of screening examination(laboratory or ECG, vital sign), subject who has clinically significant findings that are not suitable for participation in the clinical trials.
- Subject who is pregnant or breastfeeding
- Subject who does not agree to use a medically acceptable method of contraception during clinical trial.
- Besides, in case investigator determine that subject is unsuitable for study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E1K 1,200 ㎍/joint
Injected 1,200 ㎍/joint/3 mL on target lesion
|
Injection of E1K 1,200 ㎍/joint/ml on target lesion
|
Experimental: E1K 2,400 ㎍/joint
Injected 2,400 ㎍/joint/3 mL on target lesion
|
Injection of E1K 2,400 ㎍/joint/ml on target lesion
|
Placebo Comparator: Placebo
Injected 3ml of saline on target lesion
|
Injection of 3ml saline on target lesion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index)
Time Frame: 12 weeks after administration of IP versus baseline
|
Changes in the Sub-Scale(Pain) score of the WOMAC questionnaire
|
12 weeks after administration of IP versus baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain VAS 100mm
Time Frame: at 4, 8, and 12 weeks after administration of IP versus baseline
|
Changes in 100 mm Pain VAS (Pain during activity and at rest during the last 24 hours) scores
|
at 4, 8, and 12 weeks after administration of IP versus baseline
|
WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index)
Time Frame: at 4, 8, and 12 weeks after IP administration compared to baseline
|
Changes in scores by WOMAC questionnaire total score and Sub-Scale (physical function, stiffness)
|
at 4, 8, and 12 weeks after IP administration compared to baseline
|
WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index)
Time Frame: at 4 to 8 weeks after administration of IP compared to the baseline
|
Changes in the Sub-Scale(Pain) score of the WOMAC questionnaire
|
at 4 to 8 weeks after administration of IP compared to the baseline
|
KOOS
Time Frame: at 4, 8, and 12 weeks after administration of IP compared to baseline
|
Changes in KOOS questionnaire scores
|
at 4, 8, and 12 weeks after administration of IP compared to baseline
|
Quality of life(EQ-5D-5L)
Time Frame: at 4, 8, and 12 weeks after administration of IP compared to baseline
|
Changes in EQ-5D-5L questionnaire scores
|
at 4, 8, and 12 weeks after administration of IP compared to baseline
|
Frequency of Rescue drug
Time Frame: Day 0 to Day 84
|
Percentage and number of subjects who took the rescue medication during the clinical trial period
|
Day 0 to Day 84
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Young-Wan Moon, M.D., Ph.D., Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E1K-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthrosis
-
University Hospital, BordeauxCompleted
-
Sahlgrenska University Hospital, SwedenUnknownOsteoarthrosis, KneeSweden
-
NHS GrampianCompleted
-
Waldemar Link GmbH & Co. KGRecruitingOsteoarthrosis of KneeColombia
-
Cedars-Sinai Medical CenterMusculoskeletal Transplant FoundationCompletedOsteoarthrosis of the Carpometacarpal Joint of the ThumbUnited States
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedKnee Osteoarthritis | Knee Arthritis
-
Hanan JafarRecruitingKnee OsteoarthrosisJordan
-
Hanan JafarRecruitingKnee OsteoarthrosisJordan
-
Columbia UniversityAmerican Society for Surgery of the Hand; Arthritis FoundationRecruitingOsteoarthrosis of the Carpometacarpal Joint of the ThumbUnited States
-
University of UtahCompletedOsteoarthrosis of the Carpometacarpal Joint of the ThumbUnited States
Clinical Trials on E1K 1,200 ㎍/joint
-
Imperial College LondonUnknownOsteoarthritis | Rheumatoid Arthritis | Septic ArthritisUnited Kingdom
-
Barbara ŁysońCompleted
-
Assiut UniversityNot yet recruitingFigure Out the Best Method of Fixation for Management of Patients With Diabetic Fracture AnkleEgypt
-
The Second Hospital of QinhuangdaoCompletedVolar Plate Injury, Thumb, Metacarpophalangeal JointChina
-
Nicolaus Copernicus UniversityWarmia and Mazury Oncology CentreRecruitingOsteoarthritis, Knee | Osteoarthritis, HipPoland
-
American College of Foot and Ankle SurgeonsCompleted
-
Jennifer Moreno ClinicUnknownKnee Osteoarthritis | Muscle Weakness | Muscle Weakness Condition | Knee Arthritis | Knee Pain Chronic | Knee Pain Swelling | Knee Deformity | PowerUnited States
-
Peking University People's HospitalUnknownArthropathy of Knee | Arthropathy of Hip
-
VA Office of Research and DevelopmentRecruitingTransfemoral Amputation | Limb Loss | Limb AbsenceUnited States
-
Riphah International UniversityRecruitingLow Back PainPakistan